The Future of Care: Treatments and Clinical Trials for ADAD

Navigating treatment for Autosomal Dominant Alzheimer Disease (ADAD) requires a shift in perspective. While there is currently no cure, the field is moving rapidly toward disease-modifying treatments—therapies designed to slow or stop the underlying disease process rather than just masking the symptoms.

Symptomatic Management and New FDA-Approved Drugs

For many years, the only tools available were drugs developed for common, late-onset Alzheimer’s to help manage day-to-day symptoms (like donepezil or memantine) ^[1].

Recently, the medical landscape changed with the FDA approval of anti-amyloid therapies like lecanemab and donanemab for sporadic, late-onset Alzheimer’s disease ^[2]. While these are major breakthroughs, their specific effectiveness in the ADAD population is still being actively studied. Earlier clinical trials of similar drugs in ADAD patients cleared amyloid from the brain but did not significantly slow down cognitive decline ^[3]. You should discuss with your care team whether these newly approved therapies are appropriate for you or if a targeted clinical trial is a better fit.

The Risk of ARIA (Amyloid-Related Imaging Abnormalities)

It is crucial to know that all anti-amyloid therapies carry a significant risk of ARIA (Amyloid-Related Imaging Abnormalities). ARIA can manifest as temporary swelling or micro-bleeding in the brain. While it is often asymptomatic, it can sometimes cause serious complications. Anyone taking these medications—whether through an FDA-approved prescription or a clinical trial—must undergo rigorous and regular MRI monitoring to ensure their safety ^[2][4].

Lessons from the First Wave: The DIAN-TU-001 Trial

A landmark study called DIAN-TU-001 tested two anti-amyloid drugs, gantenerumab and solanezumab, specifically in ADAD families ^[4][3].

• The Result: Over four years, neither drug successfully slowed down cognitive decline compared to a placebo ^[4].
• The Silver Lining: The study proved that target engagement was possible. Gantenerumab significantly cleared amyloid plaques from the brain and even lowered levels of tau and NfL (markers of nerve damage) ^[4][3].
• Why it “Failed”: Researchers believe the doses may have been too low or started too late, and that clearing amyloid alone isn’t enough once the disease has already begun to affect memory ^[3][5].

The Next Generation: Targeted and Combination Trials

Modern research is building on these lessons by testing drugs earlier and targeting more than just amyloid ^[5][6].

Targeting Tau

Since tau tangles are more directly linked to actual memory loss, new trials are testing antibodies like E2814 ^[7]. This drug is designed to catch and neutralize tau protein before it can spread through the brain ^[7][NCT06372821].

Primary Prevention

The DIAN-TU Primary Prevention Study is a bold new approach [NCT05552157]. It targets people who carry the mutation but are 11 to 25 years away from their expected symptom onset. The goal is to see if early treatment with drugs like remternetug can prevent amyloid from ever accumulating in the first place [NCT05552157][NCT06647498].

Combination Therapy

Scientists now believe that a “cocktail” approach may be necessary—using one drug to clear amyloid and another to stop tau tangles ^[8][9]. This is a major focus of upcoming “NexGen” trials ^[6][10].

Why Clinical Trials are the “Main Avenue”

For families with ADAD, participating in research like the Dominantly Inherited Alzheimer Network (DIAN) is often the most proactive way to manage the disease [NCT00869817].

• Access: Trials provide access to cutting-edge therapies before they are available to the public.
• Expert Care: Participants are monitored by the world’s leading experts in genetic Alzheimer’s and undergo strict MRI safety protocols ^[6].
• Legacy: Even if a trial doesn’t work for one individual, the data gathered helps ensure that the next generation will have a better chance at a cure ^[5][6].